Active Pharmaceutical Ingredient (API) Market Size Worth USD 436.90 billion by 2034 | CAGR: 5.7%

The active pharmaceutical ingredient market size is expected to reach USD 436.90 billion by 2034, according to a new study by Polaris Market Research. The report “Active Pharmaceutical Ingredient (API) Market Size, Share, Trends, Industry Analysis Report: By Product Type, Form (Aqueous, Non-Aqueous Liquid, and Dry Powder), Manufacturer Type, Application, and Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The active pharmaceutical ingredient (API) market growth is driven by increasing demand for generic drugs and over-the-counter drugs worldwide. For instance, the retail sales of over-the-counter drugs in the US have risen to 43.4 billion USD in 2023 from 14.7 billion dollar USD in 2000. This represents a significant increase of 33 billion dollar USD from 2000 to 2023. Additionally, the sales revenue of OTC drugs from 2018 to 2023 has grown by 3.6%

Increasing investments and funding from public and private capitalists are anticipated to fuel active pharmaceutical market growth. Advancements in drug formulations, production, and short drug discovery timelines have been attracting investors seeking better returns on their investments. For instance, in August 2024, Vivint Pharma, a leading injectables pharmaceutical company, announced plans to build an advanced injectables manufacturing facility in Genome Valley, Hyderabad. The company will invest $48 million in the new facility, which is expected to create 1,000 jobs and strengthen Telangana’s position as a global life sciences hub. The announcement was made during a high-level meeting with Telangana's Chief Minister, Shri A. Revanth Reddy, and Minister for Industries and Commerce, Sri D. Sridhar Babu, in the US. Vivint Pharma, which already has a $8.5 million R&D center in Genome Valley, is expanding its footprint in India. The company has acquired 5.5 acres in Genome Valley, known for its world-class infrastructure and innovation ecosystem, to support its entry into international markets.  

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/active-pharmaceutical-ingredients-market/request-for-sample

Pharmaceutical companies are major consumers and manufacturers of active pharmaceutical ingredients. Increasing investment and government incentives have led to a rise in the number of new players with innovative ideas, challenging the existing pharmaceutical giants.

Active Pharmaceutical Ingredient (API) Market Report Highlights

• By form analysis, the aqueous segment is anticipated to experience substantial growth with a significant CAGR in the market. This growth is attributed to the wide range of applications of the aqueous active pharmaceutical ingredient in different forms of drugs.
• In 2024, North America dominated the API market due to the established presence of several companies within the region.
• The active pharmaceutical ingredient (API) market in China is projected for substantial growth due to the regulatory support and funding for biotech innovations within the country.

• The key market players are Pfizer; Teva Pharmaceuticals Industries Ltd.; GSK PLC; Sanofi; Eli Lilly and Company; Merck KGaA; AbbVie Inc.; F-Hoffman La Roche Ltd; AstraZeneca; Dr. Reddy’s Laboratory Ltd.; BASF Corporation; Sun Pharmaceutical Industries Ltd.; Curia Global Inc.; and Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.

Polaris Market Research has segmented the active pharmaceutical ingredient market report based on product type, form, manufacturer type, application, and region:

By Product Type Outlook (Revenue – USD Billion, 2020–2034)

• mAb
• Immunoglobulin
• Cytokines
• Insulin
• Peptide Hormones
• Blood Factors
• Peptide Antibiotics
• Vaccines
• Small Molecule Antibiotics
• Highly Potent Active Pharmaceutical Ingredient (HPAPI)
• Others

By Form Outlook (Revenue – USD Billion, 2020–2034)

• Aqueous
• Non-Aqueous Liquid
• Dry Powder

By Manufacturer Type Outlook (Revenue – USD Billion, 2020–2034)

• Captive
• Merchant

By Application Outlook (Revenue – USD Billion, 2020–2034)

• Cardiology
• Oncology
• CNS & Neurology
• Orthopedic
• Endocrinology
• Pulmonology
• Gastroenterology
• Nephrology
• Ophthalmology
• Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

API Report Scope